The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.

As this medical approach continues to become more widely adopted, the industry must adapt to help provide precise, compliant, ...

In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, ...

The partnership is centered around cutting cold chain costs and emissions with smart packaging and carbon-neutral same-day ...

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

In the final part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes best practices for balancing long-term pipeline sustainability with ...

Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by ...

In an interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, explained how AI can help address clinical trial diversity and access challenges by reducing physician workload ...

In a recent interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, discussed how AI is transforming clinical trials by reducing costs, accelerating timelines, and enhancing ...

In an exclusive sit-down with Pharma Commerce, Anne Cassity, senior vice president of government affairs for the National ...

Bruce Leuchter, CEO, Neurvati, discusses the indispensable role of patient advocates—particularly in rare and serious disease drug development—in shaping trial design, site selection, and regulatory ...

A qualitative study aimed to strengthen systematic repurposing efforts within rare disease nonprofit organizations, while ...